Following the company’s recent leadership transition, I am more intrigued than ever to see how Bloom Health Partner’s (CSE: BLMH) fiscal yearly results will be received by the market.
At the time of its FQ3 report (August 31), the company had already met its yearly revenue guidance of $25M.
Jump to once month later, and the company has announced that CEO Andrew Morton has stepped down and will be succeeded by the company’s COO, Rosemary Elliston. Given the company’s current trajectory, I’m not sure what to make of this departure by Morton. Regardless, I am still very interested to see what happens when BLMH posts yearly revenues far exceeding its guidance.
BLMH.c is currently trading at $.185, valued at $8.82 million.
https://ceo.ca/@newsfile/bloom-health-partners-announces-leadership-transition